Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

24.94
+0.44501.82%
Volume:95.13K
Turnover:2.35M
Market Cap:3.12B
PE:115.75
High:24.94
Open:24.50
Low:24.30
Close:24.49
52wk High:31.77
52wk Low:19.30
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.77
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:14.14
PE(LYR):-196.56

Loading ...

Arcutis Says FDA Approves Zoryve Cream for Plaque Psoriasis in Children as Young as 2

Reuters
·
Jun 30

FDA Approves Arcutis’ Zoryve® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

THOMSON REUTERS
·
Jun 30

Arcutis Biotherapeutics director Howard G. Welgus disposes of 4,731 common shares for $115,957.48

Reuters
·
Jun 18

Arcutis Stockholders Approve Proposals at 2026 Meeting

TIPRANKS
·
Jun 10

Arcutis Biotherapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 10

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 06

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 03

Arcutis Biotherapeutics to present at Goldman Sachs Global Healthcare Conference

Reuters
·
May 27

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
May 26

Arcutis Earnings Call Signals Momentum Amid Headwinds

TIPRANKS
·
May 11

Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4

Reuters
·
May 09

Arcutis grants 269,000 RSUs, 70,000 stock options to new hires under inducement plan

Reuters
·
May 09

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 09

Arcutis Biotherapeutics price target lowered to $34 from $35 at Morgan Stanley

TIPRANKS
·
May 08

Stock Track | Arcutis Biotherapeutics Plunges 5.23% in Pre-market Following Q1 Earnings Miss and Insider Selling

Stock Track
·
May 07

Arcutis Biotherapeutics Price Target Maintained With a $36.00/Share by Needham

Dow Jones
·
May 07

Analysts Conflicted on These Healthcare Names: Quanterix (QTRX) and Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
May 07

Stock Track | Arcutis Biotherapeutics Plunges 6.91% After Q1 Earnings Miss Estimates

Stock Track
·
May 07

Arcutis Chief Legal Officer Masaru Matsuda disposes 8,256 shares worth $192,893

Reuters
·
May 07

Arcutis Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07